FTSE MIB
34.223,50 +236,60 (+0,70%) Dow Jones
38.931,09 +78,82 (+0,20%) Nasdaq
16.337,16 -12,09 (-0,07%) Nikkei 225
38.835,10 +599,03 (+1,57%) Petrolio
78,01 -0,47 (-0,60%) Bitcoin EUR
58.645,81 -631,28 (-1,06%)
Erasca, Inc. (ERAS)
| Chiusura precedente | 2,2100 |
| Aperto | 2,2100 |
| Denaro | 2,1700 x 200 |
| Lettera | 2,2400 x 200 |
| Min-Max giorno | 2,1950 - 2,2700 |
| Intervallo di 52 settimane | 1,5100 - 3,3750 |
| Volume | |
| Media Volume | 796.201 |
| Capitalizzazione | 381,39M |
| Beta (5 anni mensile) | 1,10 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,8300 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 7,50 |
GlobeNewswireErasca to Present at the Cantor Global Healthcare Conference
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, September 26, 2023, at 8:10 am Eastern Time at the Cantor Global Healthcare Conference, which is being held at the InterContinental New York Barclay in New York, New York. M
GlobeNewswireErasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, September 12, 2023, at 5:30 pm Eastern Time at the Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Hotel in New York, N
- GlobeNewswire
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
Anti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid tumors Initial Phase 1b combination data from SEACRAFT-1 expected in Q2-Q4 2024 Dosing of first patient in pivotal SEACRAFT-2 trial in NRAS-mutant melanoma expected in H1 2024 SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapie
